Trial · NCT07886138
RET-Targeted Molecular Imaging Probes in Prostate Cancer
NCT07886138, Early phase 1, Active not recruiting, Xiangya Hospital of Central South University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. RET-Targeted Molecular Imaging Probes in Prostate Cancer. Trials, record NCT07886138. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886138
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- RET-Targeted Molecular Imaging Probes in Prostate Cancer
- NCT number
- NCT07886138
- Status
- Active not recruiting
- Phases
- Early phase 1
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Xiangya Hospital of Central South University
- Conditions
- Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Prostate Cancer
- Interventions
- RET-targeted PET/CT molecular imaging, PSMA-targeted PET/CT imaging
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Diagnostic accuracy of RET-targeted PET/CT for neuroendocrine prostate cancer (NEPC) | At the time of imaging, with pathology confirmation within approximately 1 month after imaging | The diagnostic performance of RET-targeted PET/CT for NEPC will be evaluated against pathology (the gold standard, based on biopsy or surgical specimen with neuroendocrine marker immunohistochemistry: SYP/CHGA/NSE). Diagnostic accuracy parameters, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), will be calculated. |
| Secondary | Comparison of diagnostic performance between RET-PET/CT and PSMA PET/CT | At the time of imaging | Sensitivity, specificity, PPV, and NPV of RET-targeted PET/CT will be compared with those of PSMA PET/CT, and serum neuroendocrine markers to determine the diagnostic advantage of RET-targeted imaging. |
| Secondary | Semi-quantitative tracer uptake (SUVmax and SUVmean) of lesions on RET-targeted PET/CT | At the time of imaging | The region of interest (ROI) with the highest tracer uptake in each lesion will be delineated, and SUVmax, SUVmean, and lesion size will be measured and compared between groups using independent-samples and paired t-tests. |
| Secondary | Correlation between lesion SUVmax on RET-targeted PET/CT and disease progression | Up to 5 years after enrollment | The correlation between the semi-quantitative RET tracer uptake of lesions, measured as SUVmax (unitless ratio) by region-of-interest analysis on RET-targeted PET/CT, and disease progression will be assessed. Disease progression will be determined by clinical evaluation and conventional imaging (PSMA PET/CT, mpMRI) according to clinical criteria, and progression-free survival will be recorded in months. Multivariable analysis (e.g., Cox proportional hazards regression) will be used to evaluate the relationship between baseline SUVmax and time to disease progression or death. |
| Secondary | Value of RET-targeted PET/CT for early assessment of treatment response | During follow-up after treatment (repeat imaging at least 1 week apart when needed) | Changes in RET tracer uptake will be analyzed in relation to clinical disease progression and compared with pathology, serum markers, and other imaging findings to evaluate the value of RET-targeted PET/CT for early treatment response assessment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886138
GET https://conductscience.org/api/trials/v1/NCT07886138/registered